2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4271 Long term outcomes of allogenic hematopoietic cell transplantation in acute myeloid leukemia (AML) patients ≥ 70 years undergoing reduced intensity conditioning and conventional graft-vs-host disease (GVHD) prophylaxis with tacrolimus and sirolimus

Amandeep Salhotra, MD, Gabriel Park, PharmD2, Dongyun Yang, PhD3, Monzr M. M Al Malki, MD4, Xin-Zi Emily Tang, PhD5, Vaibhav Agrawal, MD6, Karamjeet Singh Sandhu, MD7, Ahmed Aribi, MD8, Haris Ali, MD9, Ibrahim Aldoss, MD10, Salman Otoukesh, MD11, Shukaib Arslan, MD12, Brian John Ball, MD, MS13, Paul Koller, MD14, Idoroenyi Amanam, MD15, Hoda Pourhassan, MD16, Amanda Blackmon, DO17, Pamela S. Becker, MD, PhD18, Vinod Pullarkat, MD19, Eileen Smith, MD20, Guido Marcucci, MD21, Stephen J. Forman, MD22, Anthony Selwyn Stein, MD23, Andrew Artz, MD,MS24, Ryotaro Nakamura, MD25
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Duarte, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States
22 City of Hope, Duarte, California, United States
23 City of Hope, Duarte, California, United States
24 City of Hope, Duarte, California, United States
25 City of Hope, Duarte, California, United States

Background: Older patients have traditionally had poor outcomes with hematopoietic cell transplants (allo-HCT) due to adverse disease-related factors and comorbid conditions resulting in high relapse and non-relapse mortality (NRM). With the introduction of effective low intensity induction regimens using azacitidine and venetoclax for upfront treatment of older AML patients, these patients are increasingly being referred for allo-HCT. In an earlier subset analysis, our data showed excellent 5-year overall survival (OS) and leukemia free survival (LFS) in older patients undergoing fludarabine/melphalan conditioning and tacrolimus and sirolimus (T/S)-based GVHD prophylaxis (PMID: 41254192). In this retrospective analysis, we expand on our earlier analysis with a larger cohort of older patients, allowing additional assessment of the factors influencing clinical efficacy and safety of this regimen in AML patients ≥70 years.

Methods: Descriptive statistics were used to summarize patient demographics and disease characteristics. Kaplan-Meier curves and log-rank test were used to evaluate OS and LFS. Cumulative incidence curves and Gray test were used to examine differences in relapse and NRM. The assumptions of proportionality for Cox regression and Fine-Gray models were checked by corresponding tests and plots of the scaled Schoenfeld residuals.

Results: This analysis included 97 patients who underwent transplants from 2009-2024 at City of Hope. Patient median age was 72 years (range 70-78) and 69% were male. Median HCT comorbidity index (HCT-CI) was 2 (IQR 1-4) and 40% of patients had HCT-CI score ≥ 3. All donors were 8/8 HLA-matched with majority being unrelated (82%) and 20% had gender mismatched HCT recipients. The median donor age was 29 years (range 24-36) and majority of the transplants were ABO compatible (59%). Based on 2022 classification, 61% of the patients had ELN adverse risk (47% had adverse risk somatic mutations). Previous venetoclax exposure was noted in 56% of patients prior to HCT. The dose of melphalan was either 100 or 140 mg/m² and 53% patients received a dose of 140 mg/m².

With a median follow-up duration of 5.1 years (range: 1.0-11.7 years) for survivors, the 5-year OS and LFS were 58% (95% CI 47-68%) and 57% (95% CI 46-67%) respectively. The cumulative incidence of relapse and non-relapse mortality (NRM) at 2 years was 15% (95% CI 9-23%), and 21% (95% CI 13-30%) respectively. The incidence of grades 3-4 acute GVHD by day 100 was 10% (95% CI 5-17%) and 2-year incidence of extensive chronic GVHD was 49% (95% CI 38-59%). On Univariate analysis, inferior 5-year OS was associated with age≥73 years, [HR 1.91; 95% CI 1.06-3.43; p= 0.022]; adverse somatic mutations [HR 1.9; 95% CI 1.01-3.59, p=0.017], and prior venetoclax exposure [HR 1.71; 95% CI 0.89-3.29; p=0.041]. Conversely, improved 5-year OS was associated with melphalan dose of 140 mg/m² [HR 0.57; 95% CI 0.30-1.07; p=0.037].

Conclusions: In our cohort of older AML patients undergoing allogenic stem cell transplant, reduced intensity conditioning with fludarabine and melphalan results in good disease control with low 2-year relapse rate of 15%, and 5-year OS of 58%. Additional strategies are needed to reduce high rates of chronic GVHD seen with T/S-based prophylaxis.
Amandeep Salhotra, MD: Sobi - Research Funding; Incyte - Research Funding; Rigel - Research Funding; Bristol-Myers Squibb - Research Funding; OrcaBio - Research Funding; Jazz Pharma - Research Funding; Pierview - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)